AzTrials
AzTrials

Respiratory DiseaseNCT05648227

Validation of an Artificial Intelligence Enabled Diagnostic Support Software (ArtiQ.Spiro) in Primary Care Spirometry Datasets - a Retrospective Analysis

An observational study of Respiratory Disease, run by Royal Brompton & Harefield NHS Foundation Trust at 1 site in United Kingdom.

Active, not recruiting

Under way, not looking for participants. Everyone needed has enrolled. The study is still running.

Official record
Search all trials

Trial summary

A retrospective study to evaluate the diagnostic performance of an Artificial Intelligence enabled software (ArtiQ.Spiro) in UK primary care spirometry datasets. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Respiratory Disease
How many people
1,000 participants
Where
1 siteUnited Kingdom
Study dates
1 Jul 2022to 28 Feb 2025
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: The datasets, which will be analysed retrospectively, will comprise spirometry data previously collected as part of clinical spirometry pathways in primary care.

Who may be able to join

  • Adult aged 18 years or over
  • At least one of the following respiratory symptoms: cough, wheeze, shortness of breath, reduced exercise tolerance
  • Spirometry performed for clinical purposes in a non-hospital lung function setting (such as a community clinic, a GP practice, or at home)
  • Spirometry was supervised by a doctor or non-medical allied health professional

Who cannot join

  • Aged 17 or under
  • No respiratory symptoms
  • Spirometry performed for pre-operative assessment
  • Spirometry performed exclusively as part of a research study
  • Spirometry performed at home without supervision.

Trial locations and contacts

1 site in 1 country.

United Kingdom1 site
  • Harefield Hospital

    Middlesex, UB9 6JH

Other trials in United Kingdom

About this study

A retrospective study to evaluate the diagnostic performance of an Artificial Intelligence enabled software (ArtiQ.Spiro) in UK primary care spirometry datasets.

Read the detailed description

This is a retrospective analysis of existing clinical datasets with consecutive spirometry collected in a primary care setting in the UK. Individual patient data will be included if the individual meets the study protocol eligibility criteria.

Clinical datasets will be de-identified (name, date of birth, address, postcode, occupation GP, ethnicity, medications data removed). Individuals will be identified by a study ID number. The de-identified datasets will contain the minimum information needed for spirometry and ArtiQ.Spiro - namely age, smoking history, height, weight, primary respiratory symptom - and the deidentified data exported from the primary care spirometry software.

ArtiQ.Spiro Evaluation (Index Tests for Diagnosis and Quality):

A deidentified dataset will be provided to a machine learning analyst who will apply the machine learning algorithm of ArtiQ.Spiro. For each individual, the algorithm will produce a preferred diagnosis (highest probability diagnostic category) (Index Test for Diagnosis) and an assessment of spirometry quality (Acceptable, Usable, Not Acceptable/Usable) (Index Test for Quality). No clinical information outside of the spirometry dataset nor reference standard data will be made available to the analyst.

Reference Standard for Diagnosis:

The clinical dataset, together with available primary care records and secondary care records, will be used by the senior members of the direct clinical care team (Consultants in Respiratory Medicine with an interest in integrated respiratory care) to provide a reference standard for diagnosis. For each individual, two consultants will provide a diagnosis independently and blinded to the index test (ArtiQ.Spiro) output. If there is agreement, this diagnosis will be taken as the reference standard for diagnosis for the individual. If there is no agreement, a third consultant outside the direct clinical care team will be provided with the same information (but deidentified) to act as final arbitrator.

Reference Standard for Quality:

A deidentified dataset will be provided to a specialist respiratory physiologist. He/she will grade the quality of each spirometric session according to the official American Thoracic Society / European Respiratory Society 2019 Technical Statement for Standardization of Spirometry. For each patient, the quality of the spirometry session will be graded according to one of three categories: Acceptable, Usable, Not Acceptable/Usable. This will act as the reference standard for quality. The respiratory physiologists will be blinded to the output from the Index Test (ArtiQ.Spiro). The respiratory physiologists will also record time taken to evaluate the dataset.

Data Analysis:

Data analysis will be performed by the research team who will be independent to the direct clinical care team and the respiratory physiologists who will be providing the reference standards for diagnosis and quality respectively.

Medical subject headings
Respiration Disorders

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Evaluate diagnostic performance of an Artificial Intelligence enabled software (ArtiQ.Spiro) in UK primary care spirometry datasets.

    Evaluate diagnostic performance of an Artificial Intelligence enabled software (ArtiQ.Spiro) in UK care spirometry datasets.

    Measured: 24 months

Secondary outcomes (1)
  1. To evaluate the performance of an Artificial Intelligence enabled software (ArtiQ.Spiro) in the quality grading of Forced Expiratory Volume in One second (FEV1) and Forced Vital Capacity (FVC) from UK primary care spirometry datasets.

    Measured: 24 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted13 Dec 2022
  2. Study start1 Jul 2022
  3. Primary completion1 Feb 2025 (estimated)
  4. Study completion28 Feb 2025 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Other
Time perspective
Retrospective
Enrolment
1,000 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05648227
Sponsor's protocol ID
314058
Status last verified
Nov 2024
First submitted
5 Dec 2022
Last updated
31 Jan 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

An observational study of Respiratory Disease, run by Royal Brompton & Harefield NHS Foundation Trust at 1 site in United Kingdom.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: under way, not looking for participants, as of the sponsor's last update on 31 Jan 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Evaluate diagnostic performance of an Artificial Intelligence enabled software (ArtiQ.Spiro) in UK primary care spirometry datasets. (time frame: 24 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 31 Jan 2025; AzTrials last refreshed its copy on 29 Oct 2026.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in